



SIGACHI LABORATORIES LIMITED

Corporate Office: 411 Raghava Ratna Towers,
Chirag Ali Lane, Hyderabad - 500 001, Telangana (INDIA)
Ph. : 040-23204230, 23204273, E-mail: sigachilaboratories@yahoo.co.in
GSTIN: 36AACCS8220M1Z4 CIN: L24230TG1994PLC018786

Date: 31.7.2026

Head Listing & Compliance
Metropolitan Stock Exchange of India Limited
205(A), 2nd floor, Piramal Agastya Corporate Park,
Kamani Junction, LBS Road,
Kurla (West), Mumbai – 400070.

Dear Sir/Madam,

Sub: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Voluntary Disclosure regarding completion of tenure and technical oversight in filing cessation of Independent Director– Reg.

We would like to bring to your kind attention that a procedural delay/inadvertence regarding the tenure of Mrs. Shilpa Bung (DIN:08257931), who was appointed as an Additional Director in the capacity of Independent Women Director of the Company for a term of 5 (five) consecutive years from 10th February, 2021 to 9th February, 2026 and the same was duly approved by the Shareholders at the Annual General Meeting held on 24th September, 2021.

1. Facts & Nature of Oversight:

As per the terms of her initial appointment, her first 5-year tenure as an Independent Director concluded at the close of business hours on 9th February, 2026.

Due to an inadvertent administrative oversight and genuine operational lapse, the formal process for either taking note of her cessation before the Board and Shareholders was inadvertently missed prior to the tenure completion date.

Mrs. Shilpa Bung (DIN:08257931), inadvertently continued on the Board of Directors and as a member of the Board Committees, and her name was included in the quarterly Corporate Governance Reports submitted for the quarters ended 31.3.2026 and 30.6.2026 and her reappointment was not initiated prior to the expiry of her tenure as independent director.

Consequently by the operation of section 149 (10) of Companies, Act, 2013, her directorship stood automatically ceased at the close business hours on 9.2.2026.



SIGACHI LABORATORIES LIMITED

Corporate Office: 411 Raghava Ratna Towers,
Chirag Ali Lane, Hyderabad - 500 001, Telangana (INDIA)
Ph. : 040-23204230, 23204273, E-mail: sigachilaboratories@yahoo.co.in
GSTIN: 36AACCS8220M1Z4 CIN: L24230TG1994PLC018786

Unaware of the inadvertent lapse in updating corporate record, the company continued to send the meeting notices and Mrs. Shilpa Bung attended the board meetings held in March 2026 and May 2026. Furthermore, her name was inadvertently retained in the corporate governance reports filed under regulation 27(2) for the quarters ended 31.3.2026 and 30.6.2026.

2. We explicitly state and assure the Exchange that:

The non-filing of the cessation and the continuation of Mrs. Shilpa Bung was purely due to an inadvertent unwitting oversight and without any malicious intention, concealment, or motive to bypass regulatory requirements.

Mrs. Shilpa Bung has throughout satisfied all criteria of independence prescribed under Section 149(6) of the Companies Act, 2013 and Regulation 16(1)(b) of the SEBI (LODR) Regulations, 2015.

Audit Committee & Nomination and Remuneration Committee (NRC): The composition of both the Audit Committee and the NRC continued to independently fulfill the statutory quorum and structural requirements under Regulations 18 and 19 of SEBI (LODR) Regulations, 2015, even without counting her participation.

Stakeholders Relationship Committee (SRC): The Company at its Board meeting held on 4.2.2026 has broad based the Stakeholders Relationship Committee (SRC) by inducting another independent Director i.e., Dr. G.V. Narasimha Rao.

The Company further affirms that during the Board Meeting held on 4th February 2026 (prior to the tenure expiry of Mrs. Shilpa Bung, the Board had approved the appointment of Dr. G.V. Narasimha Rao as a member of the Stakeholders Relationship Committee (SRC).

Although the appointment took effect in February 2026, the inclusion of the new member was inadvertently omitted from the Corporate Governance Reports submitted for the quarters ended March 31, 2026, and June 30, 2026.

With the inclusion of Dr. G.V. Narasimha Rao, the SRC at all times maintained the mandatory minimum strength of 3 members as prescribed under Regulation 20 of SEBI (LODR) Regulations, 2015, and all decisions/proceedings of the SRC during this period remain fully valid and compliant.

3. Corrective Steps & Action Being Taken:

The company identified this operational deficiency during internal secretarial review on 31.7.2026 and immediately initiated corrective measures and e-form DIR 12 is being filed with MCA reflecting her true cessation date as 9.2.2026.



SIGACHI LABORATORIES LIMITED

Corporate Office: 411 , Raghava Ratna Towers,
Chirag Ali Lane, Hyderabad - 500 001, Telangana (INDIA)
Ph. : 040-23204230, 23204273, E-mail: sigachilaboratories@yahoo.co.in
GSTIN: 36AACCS8220M1Z4 CIN: L24230TG1994PLC018786

Along with this disclosure, the Company is in process of submitting revised Corporate Governance Reports under Regulation 27(2) for the quarters ended March 31, 2026, and June 30, 2026, accurately reflecting the date of cessation.

a. Compliance with Regulation 17(1): Even excluding Mrs. Shilpa Bung, the Company has, at all times, maintained a sufficient number of Independent Directors on its Board in full compliance with Regulation 17(1) and also committees as per the SEBI LODR Regulations and Section 149(4) of the Companies Act, 2013.

b. Validity of Quorum & Proceedings: The quorums for the Board meetings held on 30th March 2026 and 29th May 2026 were fully valid and compliant under the applicable laws based solely on the attendance of the remaining Directors and the quorums for all committee meetings held on 29th May 2026 was fully valid and compliant under the applicable laws excluding the presence of Mrs. Shilpa Bung.

c. Protection under Section 176: As provided under Section 176 of the Companies Act, 2013, the acts and resolutions passed during the aforementioned meetings remain valid and legally binding.

Since this lapse was purely an administrative oversight with zero impact on the legal composition of the Board, committee structures, or shareholder interests, we respectfully request the Exchange to take this disclosure on record, accept the revised filings, and condone the procedural delay.

We regret the inconvenience caused and assure the Exchange of our commitment to maintaining the highest standards of corporate governance. We request the Stock Exchange to kindly take this voluntary disclosure on record, treat the lapse as a bona fide administrative, clerical omission, and condone the delay.

We remain available to provide any further clarifications or documentation that the Exchange may require in this regard.

Thanking you,

Yours Faithfully

For Sigachi Laboratories Limited

(Lekha Sai Surapaneni)
Company Secretary